These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35343368)

  • 1. CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Perkins B; Showel M; Schoch L; Imus PH; Karantanos T; Yonescu R; Morsberger L; Ghiaur G; Gladstone DE; Jones RJ
    Leuk Lymphoma; 2022 Jul; 63(7):1617-1623. PubMed ID: 35343368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
    Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
    Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
    Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones.
    Osman A; Gocke CD; Gladstone DE
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):97-99. PubMed ID: 28041846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
    Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
    J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The
    Perez-Chacon G; Zapata JM
    Front Immunol; 2021; 12():627602. PubMed ID: 33912159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).
    Galieni P; Troiani E; Picardi P; Angelini M; Mestichelli F; Dalsass A; Maravalle D; Camaioni E; Bigazzi C; Caraffa P; Ruggieri M; Mazzotta S; Mattioli S; Angelini S
    Leuk Res; 2024 Aug; 143():107541. PubMed ID: 38905908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
    Rozovski U; Keating MJ; Estrov Z
    Acta Haematol; 2018; 140(1):51-54. PubMed ID: 30114695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.
    Quijada-Álamo M; Hernández-Sánchez M; Robledo C; Hernández-Sánchez JM; Benito R; Montaño A; Rodríguez-Vicente AE; Quwaider D; Martín AÁ; García-Álvarez M; Vidal-Manceñido MJ; Ferrer-Garrido G; Delgado-Beltrán MP; Galende J; Rodríguez JN; Martín-Núñez G; Alonso JM; García de Coca A; Queizán JA; Sierra M; Aguilar C; Kohlmann A; Hernández JÁ; González M; Hernández-Rivas JM
    J Hematol Oncol; 2017 Apr; 10(1):83. PubMed ID: 28399885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells.
    Ghiotto F; Marcatili P; Tenca C; Calevo MG; Yan XJ; Albesiano E; Bagnara D; Colombo M; Cutrona G; Chu CC; Morabito F; Bruno S; Ferrarini M; Tramontano A; Fais F; Chiorazzi N
    Mol Med; 2011; 17(11-12):1188-95. PubMed ID: 21785810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.
    Vetro C; Haferlach T; Jeromin S; Stengel A; Zenger M; Nadarajah N; Baer C; Weissmann S; Kern W; Meggendorfer M; Haferlach C
    Br J Haematol; 2018 Oct; 183(1):47-59. PubMed ID: 30022491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
    Balakrishna J; Basumallik N; Matulonis R; Scott D; Salem D; Jasper G; Wiestner A; Stetler-Stevenson M; Marti G; Sun C; Yuan CM
    Leuk Lymphoma; 2021 Aug; 62(8):1828-1839. PubMed ID: 33734005
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Maity PC; Bilal M; Koning MT; Young M; van Bergen CAM; Renna V; Nicolò A; Datta M; Gentner-Göbel E; Barendse RS; Somers SF; de Groen RAL; Vermaat JSP; Steinbrecher D; Schneider C; Tausch E; Bittolo T; Bomben R; Mazzarello AN; Del Poeta G; Kroes WGM; van Wezel JT; Imkeller K; Busse CE; Degano M; Bakchoul T; Schulz AR; Mei H; Ghia P; Kotta K; Stamatopoulos K; Wardemann H; Zucchetto A; Chiorazzi N; Gattei V; Stilgenbauer S; Veelken H; Jumaa H
    Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4320-4327. PubMed ID: 32047037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
    Cancer Sci; 2009 Dec; 100(12):2346-53. PubMed ID: 19824994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.
    Rigoni M; Riganti C; Vitale C; Griggio V; Campia I; Robino M; Foglietta M; Castella B; Sciancalepore P; Buondonno I; Drandi D; Ladetto M; Boccadoro M; Massaia M; Coscia M
    Oncotarget; 2015 Oct; 6(30):29833-46. PubMed ID: 26284584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.